Following the suit of AstraZeneca last February, Boehringer Ingelheim will team up with a leading R&D hub in Hong Kong to seed biotechs.
Whereas AstraZeneca focused on cancer drugs and diagnostics, the German giant will work with Hong Kong Science and Technology Parks on incubating infectious disease and immunology...
